Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Extension RCT (n=803) found improved weight loss in those that remained on semaglutide from week 20 to 68 vs those that switched to placebo (-7.9% vs +6.9%, difference -14.8%, p<0.001). Gastrointestinal adverse effects were more common with semaglutide (49.1% vs 26.1%).

Journal of the American Medical Association